Renata Medical Announces First Patient to Receive Minima Growth Stent Following FDA Approval

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Renata Medical, a leader in innovative vascular solutions for young, growing patients, proudly announces a major milestone with the successful implantation of its Minima Growth Stent in the first patient following its recent FDA approval.

“Today marks the beginning of something special,” said Dr. Darren Berman, Director of Congenital Interventional Catheterization at Children’s Hospital Los Angeles. “With the very recent FDA approval of Renata Medical's Minima Stent, we now have a stent specifically designed to treat some of the most common congenital heart defects in our youngest patients. Today, we implanted the first commercially available Minima Stent in a 2-year-old child with severe branch pulmonary artery stenosis. The procedure went smoothly, and she went home the next day.”

The Minima Growth Stent, a state-of-the-art device designed to support somatic growth, has been developed to address the limitations of traditional stenting methods in young children. Its unique Growth Technology is designed to support aortic coarctation and pulmonary artery stenosis relief and re-expand as the patient grows. The stent's approval by the FDA underscores its safety and efficacy in improving patient outcomes.

Dustin Armer, CEO of Renata Medical, expressed enthusiasm about the achievement: “Successfully implanting the first commercial Minima Growth Stent is a monumental achievement for our company. This milestone reflects our commitment to advancing medical technology and improving patient lives. We are excited to see the positive outcomes this stent will bring to the medical community and the patients we serve.”

Renata Medical continues to lead the way in developing cutting-edge solutions that address critical needs for the growing patient. The Minima Growth Stent is now available for use, with ongoing studies to further evaluate its long-term benefits.

About Renata Medical

Renata Medical, a Delaware corporation, was founded in 2019 with the focus on creating cardiovascular devices for unmet pediatric needs. Renata is committed to innovating, manufacturing and selling technology that is purposefully created for pediatric patients worldwide.

Connect with Renata at www.renatamedical.com, or follow along on LinkedIn and YouTube.

Renata and Minima are trademarks of Renata Medical.